Artiva Biotherapeutics, Inc.
General ticker "ARTV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $147.7M (TTM average)
Artiva Biotherapeutics, Inc. follows the US Stock Market performance with the rate: 49.4%.
Estimated limits based on current volatility of 4.2%: low 7.08$, high 7.70$
Factors to consider:
- Total employees count: 104 (+16.9%) as of 2025
- Top business risk factors: Limited operating history, Need additional capital, FDA approval delays, Manufacturing complexity, Market competition
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.61$, 7.48$]
- 2026-12-31 to 2027-12-31 estimated range: [1.99$, 5.90$]
Short-term ARTV quotes
Long-term ARTV plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $33.49MM | $0.25MM | $0.00MM |
| Operating Expenses | $64.16MM | $67.53MM | $89.81MM |
| Operating Income | $-30.67MM | $-67.28MM | $-89.81MM |
| Non-Operating Income | $2.02MM | $1.91MM | $5.95MM |
| R&D Expense | $50.25MM | $50.33MM | $69.54MM |
| Income(Loss) | $-28.65MM | $-65.37MM | $-83.86MM |
| Taxes | $0.07MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-27.70MM | $-65.37MM | $-83.86MM |
| Stockholders Equity | $-162.01MM | $186.64MM | $109.97MM |
| Assets | $105.11MM | $209.58MM | $130.94MM |
| Operating Cash Flow | $-47.43MM | $-55.03MM | $-76.75MM |
| Capital expenditure | $3.26MM | $0.64MM | $2.59MM |
| Investing Cash Flow | $-25.98MM | $-120.46MM | $63.41MM |
| Financing Cash Flow | $24.39MM | $162.23MM | $0.01MM |
| Earnings Per Share** | $-1.19 | $-2.68 | $-3.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.